Researchers Test New Oral Drug for Type 2 Diabetes and Obesity

Five clinical trials are recruiting participants to see how well the investigational drug orforglipron can improve blood glucose levels and reduce body weight.  

ACHIEVE 1

You may be eligible to participate if you:  

• Have type 2 diabetes and are 18 years or older

• Have an A1C 7.0-9.5% 

• Have a body mass index (BMI) of at least 23 

• Have never used insulin therapy or any oral or injectable diabetes medications 90 days prior to the trial

• Have been at a stable weight (±5%) for at least 90 days prior to the trial

• Have type 1 diabetes

• Have a history of ketoacidosis or hyperosmolar state, heart failure, acute or chronic hepatitis, or are being treated for diabetic retinopathy or macular edema

ACHIEVE 3

• Have type 2 diabetes and are 18 years or older

• Have an A1C 7.0-10.5%

• Have been on a stable dose of metformin (1500 mg more per day) or during the 90 days prior to the trial

• Have been at a stable weight (±5%) for at least 90 days prior to the trial

• Have type 1 diabetes

• Have a history of ketoacidosis or hyperosmolar state, heart failure, acute or chronic hepatitis, or are being treated for diabetic retinopathy or macular edema

ACHIEVE 4

• Have type 2 diabetes and are 18 years or older

• Have an A1C of 7.0-10.5% (if you are not taking a sulfonylurea) or an A1C 7.5-10.5% if you are on a sulfonylurea

• Have a BMI of at least 25

• Have been on a stable dose of 1-3 oral diabetes drugs (metformin, SGLT-2 inhibitors, or sulfonylureas) for at least 90 days prior to the trial 

• Have an increased risk for heart-related complications due to:

  • Coronary heart disease

  • Peripheral arterial disease

  • Cerebrovascular disease

  • Chronic kidney disease

  • Heart failure

• Have been at a stable weight (±5%) for at least 90 days prior to the trial

• Have type 1 diabetes

• Have a history of pancreatitis, a gastric emptying abnormality, acute or chronic hepatitis, or are being treated for diabetic retinopathy or macular edema 

• Have had a heart attack, stroke, or hospitalization for heart failure within 60 days prior to the trial 

ATTAIN 1 

• Are 18 years or older

• Have a BMI of:

  • At least 30 or 

  • At least 27 with one or more of the following weight-related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease

• Have at least one unsuccessful attempt to lose weight through dietary changes

• Have type 1, type 2, or any other kind of diabetes

• Have a history of ketoacidosis, hyperosmolar state, or pancreatitis

• Have a self-reported change in body weight of more than 11 pounds within 90 days of the trial

• Have family (first-degree relative) or personal history of medullary thyroid cancer or multiple endocrine neoplasia 2 (MEN2) syndrome

ATTAIN 2 

• Have a BMI of at least 27 and are 18 years or older

• Have at least one unsuccessful attempt to lose weight through dietary changes

• Have type 2 diabetes with an A1C 7.0-10.0% and are on stable treatment for at least 90 days prior to the trial, consisting of: 

• Either diet and exercise alone, or

• Up to three oral diabetes medications, excluding DPP-4 inhibitors and GLP-1 receptor agonists

You are not eligible to participate if you:

• Have any type of diabetes except type 2 diabetes 

• Have a history of ketoacidosis or hyperosmolar state, pancreatitis, or are being treated for diabetic retinopathy or macular edema

• Have family (first-degree relative) or personal history of medullary thyroid cancer or MEN2 syndrome

Are you interested? 

• Incretins: How They Impact Blood Glucose, Diabetes, and Weight Loss

• Join Ongoing Trials for Type 2 Diabetes and Obesity

• Why I Keep Participating in Clinical Trials for Diabetes Innovations